The effect of STS on change in LVEDVi remained significant when guideline‐based standard post‐MI medical therapies (β‐adrenergic blockers, ACE inhibitors or ARB, stains and diuretics), concomitant coronary risk factors (systemic hypertension, diabetes mellitus and peak NT‐proBNP levels), were added to model 1 (model 2, −4.95% relative change from pretreatment, P < 0.001). The gene discussed is NPPB; the disease is Hypertension.